Yulan Li

No ORCID on file · 7 papers in corpus · active 2020-2023

Study types

  • article 6
  • rct 1

Condition tags

  • endometriosis 4
  • chronic_pelvic_pain 2
  • dysmenorrhea 1
article 2023
A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis
Pain management ·doi:10.2217/pmt-2023-0052

WHAT IS THIS SUMMARY ABOUT?: This is a summary of research studies (known as clinical trials) called SPIRIT 1 and SPIRIT 2. The SPIRIT 1 and SPIRIT 2 studies compared how well a medicine called relugolix combination therapy worked in reliev…

rct 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…

article 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
article 2021
ASSESSMENT OF COMMON ADVERSE EVENTS OF RELUGOLIX COMBINATION THERAPY IN PREMENOPAUSAL WOMEN TREATED FOR SYMPTOMATIC ESTROGEN-DRIVEN CONDITIONS: LIBERTY AND SPIRIT STUDIES
·doi:10.1016/j.fertnstert.2021.07.038
article 2021
IL-37bΔ1-45 suppresses the migration and invasion of endometrial cancer cells by targeting the Rac1/NF-κB/MMP2 signal pathway
Laboratory investigation; a journal of technical methods and pathology ·doi:10.1038/s41374-021-00544-2

Endometrial carcinoma is one of the most common malignancies in the female reproductive system. Interleukin-37 (IL-37) is a newly discovered anti-inflammatory factor belonging to the IL-1 family. IL-37 has five different isoforms, and IL-37…

article 2021
INTEGRATED LONG-TERM BONE MINERAL DENSITY (BMD) OUTCOMES IN WOMEN RECEIVING RELUGOLIX COMBINATION THERAPY IN LIBERTY AND SPIRIT STUDIES VS NON-TREATED WOMEN
·doi:10.1016/j.fertnstert.2021.07.144
article 2020
EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2)
·doi:10.1016/j.fertnstert.2020.08.238